DiaMedica Therapeutics (DMAC) Share-based Compensation (2017 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Share-based Compensation came in at $822000.0 in Q1 2026, down 5.19% year-on-year from $867000.0 in Q1 2025, and down 31.04% quarter-over-quarter from $1.2 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Share-based Compensation (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Share-based Compensation history runs 10 years deep, the most recent figure standing at $822000.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation fell 5.19% year-over-year to $822000.0 in Q1 2026; TTM through Mar 2026 was $3.8 million, a 54.26% increase from a year earlier, with the FY2025 full-year figure at $10.6 million, up 135.56% from the prior year.
- Share-based Compensation declined to $822000.0 in Q1 2026 per DMAC's latest filing, from $1.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $1.2 million in Q4 2025 and bottomed at $308000.0 in Q1 2022.
- The 5-year median for Share-based Compensation is $456000.0 (2023), against an average of $584588.2.
- Across the five-year window, Share-based Compensation sank 39.73% in 2022 and surged 102.38% in 2025, its largest moves.
- Year by year, Share-based Compensation stood at $411000.0 in 2022, then increased by 10.95% to $456000.0 in 2023, then rose by 29.17% to $589000.0 in 2024, then jumped by 102.38% to $1.2 million in 2025, then plunged by 31.04% to $822000.0 in 2026.
- Per Business Quant, the three latest DMAC Share-based Compensation figures stand at $822000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.0 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | DiaMedica Therapeutics | 366.87 Mn | 366.87 Mn | - | 822,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 822,000.00 |
| Mar 31, 2026 | 822,000.00 |
| Dec 31, 2025 | 1.19 Mn |
| Dec 31, 2025 | 1.19 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.02 Mn |
| Jun 30, 2025 | 771,000.00 |
| Jun 30, 2025 | 771,000.00 |
| Mar 31, 2025 | 867,000.00 |
| Mar 31, 2025 | 867,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Dec 31, 2024 | 589,000.00 |
| Sep 30, 2024 | 565,000.00 |
| Sep 30, 2024 | 565,000.00 |
| Jun 30, 2024 | 443,000.00 |
| Jun 30, 2024 | 443,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Mar 31, 2024 | 488,000.00 |
| Dec 31, 2023 | 456,000.00 |
| Dec 31, 2023 | 456,000.00 |